Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Clinical trial NCT00311480 · COMPLETED

Trial details

NCT number: NCT00311480
Sponsor: Novartis
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Pandemic Influenza Disease

Start date: 2006-03-01
Enrollment: 520

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.